OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors

HTML

Year: 2009
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2009.27.15_suppl.3500
Authors: G. Shapiro, E. Kwak, J. Baselga, J. Rodon, C. Scheffold, A. D. Laird, C. Bedell, G. Edelman
Institutions: Exelixis (United States), Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari
Language: English

Topic: PI3K/AKT/mTOR signaling in cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: idelalisib, PI3K inhibitors, class I PI3K, solid tumors, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, rash, thrombosis, hyperglycemia, non-small cell lung cancer, breast cancer, non-Hodgkin lymphoma, pancreatic cancer, continuous daily dosing
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W88663011
Cites:
Cited by: 49
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security